Spero Therapeutics

$16.75 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720. SPR994 is novel oral formulation of tebipenem, a carbapenem-class antibiotic. SPR994 is effective against a broad spectrum of MDR bacterial infections, its initial focus is on the treatment of cUTIs. Potentiator platform that enables to develop drugs that expand the spectrum and potency of existing antibiotics, including inactive antibiotics, against Gram-negative bacteria. SPR720 is novel oral therapy product candidate designed for the treatment of NTM, a rare lung infection often occurring in patients with compromised immune systems, including HIV, or respiratory conditions, such as cystic fibrosis, asthma and bronchiectasis.

Stock Analysis

last close $16.75
1-mo return -12%
3-mo return 11.7%
avg daily vol. 89.95T
52-week high 23.64
52-week low 11.75
market cap. $547M
forward pe -
annual div. -
roe -92.1%
ltg forecast -
dividend yield -
annual rev. $18M
inst own. 55.8%
baraka

Subscribe now for daily local and international financial news

Subscribe